Investment Rating - The report maintains a "Buy" rating for the company, indicating an expectation that the company's stock will outperform the benchmark index by more than 20% over the next 6-12 months [2][7]. Core Views - The company has experienced a significant year-on-year increase in net profit attributable to the parent company, with a growth of 1,481.94% in the first half of 2025. This is attributed to cost reduction and efficiency improvements, alongside a recovery in the agricultural protection industry [2][10]. - The report highlights the company's strategic positioning within the agricultural protection sector, which is seeing a recovery in market demand, and notes the orderly advancement of its product layout [2][7]. Financial Performance Summary - For the first half of 2025, the company achieved revenue of 3.15 billion RMB, a year-on-year increase of 5.76%, and a net profit of 224 million RMB, reflecting a substantial increase of 1,481.94% [10][11]. - In the second quarter of 2025, revenue reached 1.64 billion RMB, up 8.43% year-on-year, with a net profit of 174 million RMB, marking a year-on-year increase of 1,419.69% [12]. - The company's gross margin improved to 26.72% in the first half of 2025, up 3.56 percentage points year-on-year, while the net margin reached 8.36%, an increase of 6.91 percentage points [10]. Business Segment Performance - The agricultural protection business generated revenue of 1.70 billion RMB in the first half of 2025, with a gross margin of 24.99%, an increase of 9.48 percentage points year-on-year [10]. - The pharmaceutical business reported revenue of 1.02 billion RMB, a year-on-year increase of 42.80%, with a gross margin of 42.75% [10]. - The fine and functional chemicals segment achieved revenue of 265 million RMB, a significant increase of 109.18% year-on-year, although it reported a negative gross margin of -19.05% [10]. Profit Forecast and Valuation - The report adjusts profit forecasts for 2025-2027, projecting net profits of 318 million RMB, 421 million RMB, and 530 million RMB, respectively. Corresponding earnings per share are expected to be 0.35 RMB, 0.46 RMB, and 0.58 RMB, with price-to-earnings ratios of 32.6, 24.6, and 19.6 times [7][9].
联化科技(002250):归母净利润同比大幅增长,植保业务毛利率提升